Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1841-1850 Newer>

The Motley Fool March 4, 2005 Charly Travers	The Sharks Are Circling Major stock declines are too often followed by class action suits in the drug industry. When something bad happens, it is an unfortunate event, but it doesn't automatically mean that management was recklessly misleading investors.
IndustryWeek March 1, 2005	Pharmaceutical Misallocation Some 75% of surveyed pharmaceutical industry executives identified long-term resource allocation as their chief challenge.
BusinessWeek March 14, 2005 Arnst & Barrett	Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments
BusinessWeek March 14, 2005 John Carey	Tysabri's Painful Lessons Biogen's sudden withdrawal of the multiple sclerosis drug illustrates the dangers of trying to alter the immune system's workings
BusinessWeek March 14, 2005 Gene G. Marcial	The Allure Of Impax "Impax' pipeline is impressive. So it's valuable as a stand-alone or as a buyout," says Robin Manners West of New Mexico's State Investment Council.
The Motley Fool March 3, 2005 Tim Beyers	Simple, Beautiful, Cantel A wonderfully simple earnings release hides a cash-flow machine at medical products firm Cantel Medical.
The Motley Fool March 3, 2005 Rich Duprey	Chiron Back From the Dead British authorities give vaccine manufacturer the go-ahead to restart facility. Investors can breathe a sigh of relief.
The Motley Fool March 3, 2005 Brian Gorman	Bayer Heals Itself The latest earnings report suggests things are looking up -- and drug development may soon yield more good news for investors.
The Motley Fool March 2, 2005 Brant David McLaughlin	Merck's Road to Recovery Merck didn't get to where it is by being shortsighted, and management has no plans to start now. Investors would be wise not to take on an excessively negative attitude toward the company in the wake of some dark news.
The Motley Fool March 2, 2005 Bill Mann	How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns.
<Older 1841-1850 Newer> Return to current articles.